Pfizer spoke with China about a license that would allow Chinese drugmakers to manufacture a generic version of its COVID-19 treatment, Paxlovid. China is currently experiencing a surge of COVID-19 cases, which are overwhelming hospitals. (Reuters)

AbbVie said it will spend $30 million upfront for a partnership with Immunome that will bolster their antibody research through Immunome’s Discovery Engine platform. The move will “enhance our existing oncology pipeline” and “unlock novel cancer biology,” AbbVie VP of oncology discovery research Steve Davidsen said. (Benzinga)

Amgen agreed to spend as much as $2 billion in Synaffix’s largest ADC licensing deal to date. The Dutch biotech — running in the same circles as ADC Therapeutics, Seagen, MacroGenics and Emergence Therapeutics — said that it secured a licensing deal with Amgen to develop new ADCs. (Endpoints News)

Moderna announced a partnership with small biotech CytomX Therapeutics Inc. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop “messenger RNA-based conditionally activated therapeutics.” (MarketWatch)

Researchers at startup LinusBio have developed an autism test that can pinpoint markers in hair strands. The evidence it works is still preliminary, however, and experts agree more research is needed. (NBC News)